AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02905825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathID® Hp System
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Study NCT02905825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BreathID® Hp Lab System
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Study NCT00417404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aquasol A
Description: 10,000 IU three times weeks, by intramuscular injection
Study NCT00417404 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: sham injection
Study NCT02905825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool Test
Description: Each subject was asked to perform a stool test in parallel to the breath test.
Study NCT01308359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV glucose 5%
Description: 500 ml glucose 5% within 30 minutes
Study NCT03543527 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01523223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo CD8 memory T-cell infusion
Study NCT02208232 — intervention group
Intervention type: PROCEDURE
Intervention: cataract surgery
Description: cataract surgery with implantation of intraocular lens
Study NCT04016441 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a survey online
Study NCT02575911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser System
Description: Used for the creation of a corneal flap in patients undergoing LASIK surgery
Study NCT02575911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Study NCT03664518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
Study NCT03775720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
Study NCT03418090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 129Xe MRI
Description: Evaluation of pulmonary function
Study NCT03418090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 133XE scintigraphy
Description: Evaluation of pulmonary function
Study NCT01751763 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: treatment (including dose, duration, modification) decided by the investigator.
Study NCT02100202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02100202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin (Curcuma longa rhizomes extract)
Study NCT02100202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin-WD (Water dispersible curcuminoids)
Study NCT02100202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MaQxan (Tagetes erecta flower extract)
Study NCT01431651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics,digestive enzyme
Description: patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
Study NCT01872078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4901 (oral)
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Study NCT04452253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
Study NCT04452253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 live
Description: PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
Study NCT04452253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 heat-treated
Description: The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
Study NCT04452253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule contains microcrystalline cellulose.
Study NCT00242619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Rosiglitazone was administered at two different doses over the 12-week period.
Study NCT00639847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-home asthma management program (AMP) provided by nurses
Description: The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
Study NCT00639847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-home asthma management program (AMP) provided by respiratory therapists
Description: The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
Study NCT04241991 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Active laser
Description: Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
Study NCT04241991 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
Study NCT00117208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol
Description: 400mg BD for 12 weeks
Study NCT00117208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mannitol + pulmozyme
Description: combination
Study NCT00117208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase alpha
Description: 2.5mg daily for 2 weeks
Study NCT01872078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match AZD4901
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Study NCT01392638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
Study NCT01392638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
Study NCT03984292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teaching of laparoscopic skills on a box simulator
Description: The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
Study NCT01864850 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard RT
Description: 70 Gy / 7 weeks / 2 Gy per fraction
Study NCT01864850 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT
Description: 55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
Study NCT01308359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: saline
Study NCT03667989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assessment of cardiac sympathetic innervation by 123I-MIBG
Description: Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
Study NCT04422691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
Study NCT01807325 — intervention group
Intervention type: PROCEDURE
Intervention: pancreas biopsy
Description: patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
Study NCT03710356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol 200 MG
Description: DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
Study NCT02076854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Message Intervention
Study NCT01035034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid MIDCAB/PCI
Description: MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES).
Study NCT01035034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with DES
Description: Polymer-based Sirolimus-Eluting Stents (SES)
Study NCT02789215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs
Study NCT00873613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of Non-dilated retinal photography
Description: Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
Study NCT04536051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 single dose + paracetamol
Description: Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol
Study NCT04536051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY single dose + paracetamol
Description: Single dose of MenACWY + paracetamol
Study NCT04536051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 two dose + paracetamol
Description: Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol
Study NCT04536051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY prime & saline placebo boost + paracetamol
Description: MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
Study NCT02661659 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multipeptide vaccine S-588210
Study NCT00966329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: HAART regimen including 2 NRTI/NtRTIs plus maraviroc
Study NCT00966329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz).
Study NCT04052347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making with a Decision-aid
Description: A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
Study NCT04052347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine shared decision-making
Description: control group
Study NCT05386810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine
Description: Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
Study NCT05386810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV control vaccine
Description: Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
Study NCT05386810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: single-person sIPV control vaccine
Description: Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection.
Study NCT00194610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
Study NCT00194610 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
Study NCT03765580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish
Description: Lunch containing fish
Study NCT03765580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Lunch containing no fish
Study NCT05663008 — intervention group
Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
Description: 128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
Study NCT00703963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INRatio monitor by Hemosense
Description: Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
Study NCT00703963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
Study NCT03410719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi GI
Description: subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or >70 (Hi-GI group).
Study NCT03149159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
Study NCT03149159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
Study NCT03149159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Steriotactic radiation therapy
Description: The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
Study NCT03072043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
Study NCT03072043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
Study NCT01731847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the combination group
Description: Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
Study NCT00610844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary radiofrequency ablation
Description: CT-guided pulmonary radiofrequency ablation
Study NCT03506139 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
Study NCT02779777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral tablet
Study NCT01943786 — intervention group
Intervention type: DRUG
Intervention: FOLFIRI + Cetuximab
Description: Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
Study NCT01090102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine (5-aminosalicylic acid, Apriso)
Description: Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
Study NCT01090102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
Study NCT03859193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Video
Description: A 10 - 15 minute video
Study NCT00510289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice a day until progression or unacceptable toxicity develops.
Study NCT03030820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Cleaning
Description: This is standard of care dental cleaning as is guided by the initial dental evaluation
Study NCT03237416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
Study NCT03237416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast